slide1
Download
Skip this Video
Download Presentation
FORO DE I+D BIOMEDICA GLOBAL

Loading in 2 Seconds...

play fullscreen
1 / 21

European Biotech Industry - PowerPoint PPT Presentation


  • 323 Views
  • Uploaded on

FORO DE I+D BIOMEDICA GLOBAL. LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA: CHINA, SINGAPUR Y COREA DEL SUR. STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE BIOSCIENCES AND BIOTECH GROWTH. Carlos Martinez-A. Communicating biotech .... . BioPlastic is plastic BioDiesel is diesel.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'European Biotech Industry' - Patman


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

FORO DE I+D BIOMEDICA GLOBAL

LA NUEVA GEOGRAFIA DE LA INNOVACION BIOMEDICA:

CHINA, SINGAPUR Y COREA DEL SUR

STRENGHTS, CHALLENGES AND DRIVERS OF THE CHINESE

BIOSCIENCES AND BIOTECH GROWTH

Carlos Martinez-A

slide2

Communicating biotech ....

BioPlastic is plastic

BioDiesel is diesel.

Corn is corn

Soya is soya

Medicines are medicines

european biotech industry
European Biotech Industry?

Here?

Here?

Here?

Here?

Here?

Here?

Follow on

Pre-seed

Seed

VC

IPO

Debt

Or along the capital pipeline?

european biotech industry4
European Biotech Industry
  • Fragmentation  lack of critical mass:
    • Product markets
    • Financial markets
    • Regulatory frameworks
    • Centers of excellence and clusters
  • Business attitude
  • Political attitude
  • “10-year gap”
  • Lack of all forms of finance
european biotech industry5
European Biotech Industry

Source: Critical I and EuropaBio

european biotech industry6
European Biotech Industry

Source: Critical I and EuropaBio

slide8
La productividad de las biotech es superior a la de las farmacéuticas

European Biotech Productivity

Fuente: Ernst & Young, Beyond Borders (Biotech Report), Nov 2005

slide9

European Biotech Productivity

Durante el 2005 las compañías de biotecnología han experimentado una rentabilidad superior a las Farmacéuticas y a los principales índices

Fuente: Bloomberg, Abn Amro

slide10

European Biotech Productivity

European Biotech Industry

Valor de capitalización bursátil

(miles de millones de dólares)

Programas en fase clínica

(Numero de programas)

958

… En su conjunto el valor de capitalización bursátil del sector es igual al valor bursátil de Pfizer y GSK …. con 8 veces el potencial de crecimiento

343,3

334,9

Fase II/III

110

Fase I

Fase II/III

Fase I

World Biotech Sector

Pfizer y Glaxosmithkline

World Biotech Sector

Pfizer y Glaxosmithkline

Fuente: GS Global research 2003, SG Cowen Pipeline Plus March 2004, BB Biotech

european biotech industry11
European Biotech Industry

Political risks

VALUE

R&D risks

IP risks

Financing risks

Regulatory risks

RISK

Market risks

TIME

european biotech industry12

Political support

European Biotech Industry

VALUE

R&D risks

Political risks

IP risks

Financing risks

Regulatory risks

RISK

Market risks

TIME

slide13

Ingenio 2010

The Spanish Government has presented the INGENIO 2010 program to stimulate R&D+i

  • Reach 2% of the GDP for R&D in 2010 and 1.5% in 2007
  • Reach 55% private contribution in R&D investment in 2010
  • Achieve the EU mean in the percentage of the GDP assigned for TIC, to go from 4.8% in 2004 to 7% in 2010

OBJECTIVES

Budget ≈ 8.000 M€

  • CENIT: public-private collaboration
    • CENIT projects
    • Fund of Capital Risk funds
    • “Torres Quevedo” Program
    • Increased the number of spin-offs by four folds
  • CONSOLIDER: increase critical mass and researcher excellence
  • [email protected]: convergence of the EU with the Information Society

INSTRUMENTS

slide14

CSIC: over 60 years devoted to R&D

1907: Council for the Extension of Studies and Scientific Research

Santiago Ramón y Cajal

The Nobel Prize in Physiology or Medicine 1906

Severo Ochoa

The Nobel Prize in Physiology or Medicine 1959

slide15

PAIS VASCO

CANTABRIA

  • Organised:
    • Network of 116 Institutes

(including 40 joint Centres

with other Institutions)

    • 134 Associated Units

ASTURIAS

[1]

[2]

2

GALICIA

NAVARRA

3+[1]

CATALUÑA

[1]

13+[4]+(3)

CASTILLA-LEON

ARAGON

2+[3]

3+[3]

MADRID

BALEARES

33+[7]+(5)

[1]

C. VALENCIANA

CASTILLA-LA

MANCHA

3+[7]

EXTREMADURA

[1]

1+[1]

MURCIA

1

ANDALUCIA

13+[7]+(1)

ROMA

1

1

CSIC: over 60 years devoted to R&D

  • Performing:
    • Multidisciplinary Scientific and Technological Research
    • Scientific and Technical Assessments
    • Training of scientific and technical personnel
    • Management of infrastructures
  • Collaborating with:
    • Universities
    • Other public R&D Organisations
    • Industries
    • Enterprises, Professional

Associations and Foundations

    • Regional Governments
slide16

NATIONAL RESEARCH

PLAN OF R&D

INDUSTRY

40,7%

18,%

15,%

16,%

REGIONAL

GOVERNMENTS

EU

OTHERS

7,9%

TOTAL: 204 M€

HUMAN RESOURCES

2.400 Research Staff

4.000 Postgraduate students and Postdocs

4.000 Administrative and Technicians

TOTAL : 10.400

Budget & Human Resources

BUDGET

TOTAL BUDGET: 530 M€

MEC

61,5 %

38,5 %

External resources

slide17

CSIC Institutes in the Scientific Area of Biology and Biomedicine

Andalusian Center of Developmental Biology. CABD, Sevilla

Andalusian Center of Molecular Biology and Regenerative Medicine. CABIMER, Sevilla

Center of Cardiovascular Research. CIC, Barcelona

Center for Regenerative Medicine, CMR, Barcelona

Center of Biological Research. CIB, Madrid

National Center of Biotechnology. CNB, Madrid

Institute of Molecular and Cellular Biology “Primo Yúfera”. IBMCP, Valencia

Institute of Molecular and Cellular Biology of Cancer. IBMCC, Salamanca

Institute of Molecular Biology of Barcelona. IBMB, Barcelona

Laboratory of Plant Genetics-IBMB. Barcelona

Center of Molecular Biology, CBM, Madrid

Institute of Biology and Molecular Genetics. IBGM, Valladolid

Institute of Biomedicine of Valencia. IBV, Valencia

Institute of Plant Biology and Photosynthesis. IBVF, Sevilla

Institute of Biomedical Research “Alberto Sols”. IIB, Madrid

Institute of Biomedical Research of Barcelona. IIBB, Barcelona

Institute of Biochemical Microbiology. IMB, Salamanca

Institute of Neurobiology “Ramón y Cajal”. INRC, Salamanca

Institute of Neurosciences of Alicante. INA, Alicante

Institute of Parasitology and Biomedicine “López Neyra”. IPBLN, Granada

Unit of Biophysics. UBF, Bilbao

21 Research Centers

knowledge transfer
KNOWLEDGE TRANSFER
  • EMPRESAS DE BASE TECNOLÓGICA
slide20

CSIC – Asia Collaboration

CSIC’s Subscribed Agreements

CHINA

Chinese Academy of Sciences (CAS)

National Natural Science Foundation (NSFC)

Bottom-up approach

JAPAN

Japan Society for the Promotion of Science (JSPS)

Republic of KOREA

Korea Science and Engineering Foundation (KOSEF)

Joint projects and

exchange of researchers

TAIWAN

National Science Council (NSC)

VIETNAM

Vietnamese Academy of Science and Technology (VAST)

slide21

Thank you!

Gracias!

ad